.webp&w=384&q=75){kind=logo}
Loading, please wait...
Loading, please wait...
SANAD II directly addressed an everyday epilepsy question: how do newer antiseizure medicines compare with established first-line therapy? In the focal-epilepsy trial, 990 participants were randomised to lamotrigine, levetiracetam or zonisamide. Levetiracetam did not meet the prespecified criteria for non-inferiority to lamotrigine for time to 12-month remission, while zonisamide met the non-inferiority criterion in the intention-to-treat analysis. In the per-protocol analysis, however, lamotrigine was superior to both newer treatments for the primary remission outcome, and treatment failure was less frequent with lamotrigine. Adverse reactions were also somewhat less common with lamotrigine. The trial was open-label, which may have influenced decisions about treatment failure or adverse effects. Nevertheless, its pragmatic design and long follow-up make it highly relevant to routine practice. For HCPs, the message is that newer drugs should not automatically displace established first-line therapy simply because they are newer or perceived as easier to use. Drug selection still depends on seizure type, comorbidity, reproductive considerations, tolerability and patient preference.
Read summarized clinical updates, watch expert medical content, and earn CME certifications right from your smartphone.
Open your smartphone camera to scan and install.
SANAD II directly addressed an everyday epilepsy question: how do newer antiseizure medicines compare with established first-line therapy? In the focal-epilepsy trial, 990 participants were randomised to lamotrigine, levetiracetam or zonisamide. Levetiracetam did not meet the prespecified criteria for non-inferiority to lamotrigine for time to 12-month remission, while zonisamide met the non-inferiority criterion in the intention-to-treat analysis. In the per-protocol analysis, however, lamotrigine was superior to both newer treatments for the primary remission outcome, and treatment failure was less frequent with lamotrigine. Adverse reactions were also somewhat less common with lamotrigine. The trial was open-label, which may have influenced decisions about treatment failure or adverse effects. Nevertheless, its pragmatic design and long follow-up make it highly relevant to routine practice. For HCPs, the message is that newer drugs should not automatically displace established first-line therapy simply because they are newer or perceived as easier to use. Drug selection still depends on seizure type, comorbidity, reproductive considerations, tolerability and patient preference.
4 weeks back
A bioengineered oral nanozyme microsupplement converts pathological ROS into a protective polydopamine hydrogel shield. By curbing neutrophil extracellular traps and balancing T cells, this platform outperforms standard 5-ASA in preclinical colitis models, opening new paths for sustained remission.
3 days back
Recent research reveals that downregulating YAP1/TAZ-TEAD via Hippo signaling triggers spontaneous human trophoblast syncytialization in 3D cultures, illuminating placental biology and preeclampsia.
4 weeks back
Abdominal aortic aneurysm rupture remains a catastrophic vascular emergency. Groundbreaking research reveals that USP53 accelerates aneurysm progression by reprogramming smooth muscle cell metabolism toward aerobic glycolysis, highlighting a promising target beyond conventional diameter-based surveillance.
4 days back
A breakthrough study leverages natural language processing to accurately identify incident medication-related osteonecrosis of the jaw and track antiresorptive drug holidays from clinical narratives in electronic health records, advancing osteoporosis pharmacovigilance and dental safety.
4 days back
Recent research defines ferro-aging as a conserved iron-lipid axis driving organ decline across primates. Age-related iron dyshomeostasis stimulates ACSL4-mediated lipid peroxidation, promoting cellular senescence. Notably, vitamin C directly inhibits ACSL4, suppressing phospholipid oxidation and multi-organ decay.
5 days back
